Description
Brigantinib
Each film-coated tablet contains: Brigatinib. … 90 mg
INDICATION
LuciBriga is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
DOSAGE AND USE
90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciBriga during Pregnancy and Lactation.
Brigatinib
Each film-coated tablet contains: Brigatinib. … 180 mg
INDICATION
LuciBriga is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
DOSAGE AND USE
90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciBriga during Pregnancy and Lactation.
Reviews
There are no reviews yet.